Skip to main content
SpringerLink
Log in

Therapeutic Drug Monitoring in Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome

  • Chapter
Handbook of Drug Monitoring Methods

  • 2611 Accesses

Summary

Human immunodeficiency virus (HIV) causes acquired immunodeficiency syndrome (AIDS), and it is estimated that 42 million people are infected with HIV. Four classes of drugs are used today to treat people with AIDS; nucleoside reverse transcriptase (NRTIs), non-NRTIs (NNRTIs), protease inhibitors (PIs), and entry blockers (EIs). Evidence is accumulating that both PIs and NNRTIs are good candidates for therapeutic drug monitoring (TDM). However, there is little evidence suggesting that TDM of NRTIs would be helpful other than to assess compliance/adherence to the drug regime. There is no commercially available immunoassay for routine monitoring of antiretrovirals in serum. The current methods for TDM of these drugs include high-performance liquid chromatography (HPLC) and tandem mass spectrometry. Tandem mass spectrometry is a superior technique to HPLC for analysis of these antiretrovirals.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. The economics of HIV in Africa [editorial]. Lancet 2002: 360;1.

    Google Scholar 

  2. UNAIDS. AIDS epidemic update: December 2001. Available at http://www.unaids.org/epidemicpupdate/reportpdec01/index.html (accessed June 2002).

    Google Scholar 

  3. Centers for Disease Control and Prevention, Divisions of HIV/AIDS Prevention. Human immunodeficiency virus type 2. Available at http://www.cdc.gov/hiv/pubs/facts/hiv2.htm (accessed June 2002).

    Google Scholar 

  4. Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA 2000;283: 2653–2654.

    Article  PubMed  Google Scholar 

  5. Office of Communications and Public Liaison, National Institute of Allergy and Infectious Diseases. Fact Sheet. Bethesda, MD: National Institutes of Health; May 2001.

    Google Scholar 

  6. The National Institute of Allergy and Infectious Diseases (March 1999). Available at http://www.niaid. nih.gov/factsheets/hiv_inf.htm (accessed June 2002).

    Google Scholar 

  7. Centers for Disease Control and Prevention. HIV/AIDS surveillance report.1999;11: 1–44.

    Google Scholar 

  8. Dasgupta A, Okhuysen PC. Pharmacokinetic and other drug interactions in patients with AIDS. Ther Drug Monit 2001;23: 591–605.

    Article  PubMed  CAS  Google Scholar 

  9. van Heeswick RPG. Critical issues in therapeutic drug monitoring of antiretroviral drugs. Ther Drug Monit 2002;24: 323–331.

    Article  Google Scholar 

  10. Soldin OP, Soldin SJ. Therapeutic drug monitoring in pediatrics. Ther Drug Monit 2002;24: 1–8.

    Article  PubMed  CAS  Google Scholar 

  11. Gerber JG. Using pharmacokinetics to optimize antiretroviral drug-drug interactions in the treatment of human immunodeficiency virus infection. Clin Infect Dis 2000;30(Suppl 2): S123–S129.

    Article  PubMed  CAS  Google Scholar 

  12. Back DJ, Khoo SH, Gibbons SE, et al. Therapeutic drug monitoring of antiretrovirals in human immunodeficiency virus infection. Ther Drug Monit 2000;22: 122–126.

    Article  PubMed  CAS  Google Scholar 

  13. Merry C. Therapeutic drug monitoring of antiretroviral drugs. Northwest Univ Rep HIV/AIDS 2000;4: 1–8.

    Google Scholar 

  14. van Heeswick RPG, Veldkamp AI, Mulder JW, et al. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS 2000;14: F77–F82.

    Article  Google Scholar 

  15. Durant J, Clevenbergh P, Garraffo R, et al. Importance of protease inhibitor plasma levels in HIV infected patients treated with genotypic-guided therapy: pharmacological data from the Viradept study. AIDS 2000;14: 1333–1339.

    Article  PubMed  CAS  Google Scholar 

  16. Burger D, Hugen P, Droste J, et al. Therapeutic drug monitoring (TDM) of nelfinavir (NFV) and indinavir (IDV) in treatment-naïve patients improves therapeutic outcome after 1 year: results from ATHENA. In: Abstracts of the First IAS Conference on HIV Pathogenesis and Treatment; 2001; Buenos Aires, Argentina. Abstract 30.

    Google Scholar 

  17. Lebergeber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999;353: 863–868.

    Article  Google Scholar 

  18. Erb P, Battegay M, Zimmerli W, et al. Effect of antiretroviral therapy on viral load, CD4 cell count, and progression to acquired immunodeficiency syndrome in a community human immunodeficiency virus-infected cohort: Swiss Cohort Study. Arch Intern Med 2000;160: 1134–1140.

    Article  PubMed  CAS  Google Scholar 

  19. Junghans C, Low N, Chan P, et al. Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study. AIDS 1999;13: 2547–2554.

    Article  PubMed  CAS  Google Scholar 

  20. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk of virologic failure and adverse drug reactions. Ann Intern Med 1999;131: 81–87.

    PubMed  CAS  Google Scholar 

  21. Veldkamp AI, Weverling GJ, Lange JM, et al. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS 2001;15: 1089–1095.

    Article  PubMed  CAS  Google Scholar 

  22. Hoetelmans RMW, Reijers MHE, Weverling GJ, et al. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy. AIDS 1998;12: F111–F115.

    Article  PubMed  CAS  Google Scholar 

  23. Gatti G, Di Biagio A, Casazza R, et al. The relationship between ritonavir plasma levels and side effects: implications for therapeutic drug monitoring. AIDS 1999;13: 2083–2089.

    Article  PubMed  CAS  Google Scholar 

  24. Sadler BM, Gillotin C, Lou C, et al. Pharmacokinetic and pharmacodynamic study of the immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing. Antimicrob Agents Chemother 2001;45: 30–37.

    Article  PubMed  CAS  Google Scholar 

  25. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1–infected patients. AIDS 2001;15: 71–75.

    Article  PubMed  CAS  Google Scholar 

  26. Fletcher CV, Anderson PL, Kakuda TN, et al. Concentration controlled compared with conventional antiretroviral therapy for HIV infection. AIDS 2002;16: 551–560.

    Article  PubMed  Google Scholar 

  27. Anderson PL, Fletcher CV. Clinical pharmacologic considerations for HIV-1 protease inhibitors. Curr Infect Dis Rep 2001;3: 381–387.

    Article  PubMed  Google Scholar 

  28. Fletcher CV, Balfour HH Jr. Variability in zidovudine serum concentrations. Pharmacotherapy 1996;16: 1154–1158.

    PubMed  CAS  Google Scholar 

  29. Barry MG, Merry C, Lloyd J, et al. Variability in trough plasma saquinavir concentrations in HIV case for therapeutic drug monitoring. Br J Clin Pharmacol 1998;45: 501–502.

    Article  PubMed  CAS  Google Scholar 

  30. Moyer TP, Temesgen Z, Enger R, et al. Drug monitoring of antiretroviral therapy for HIV-1 infection: method validation and results of a pilot study. Clin Chem 1999;45: 1465–1476.

    PubMed  CAS  Google Scholar 

  31. Titier K, Lagrange F, Pehourcq F, et al. High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and two non-nucleoside reverse transcriptase inhibitors in human plasma. Ther Drug Monit 2002;24: 417–424.

    Article  PubMed  CAS  Google Scholar 

  32. Villani P, Feroggio M, Gianelli L, et al. Antiretrovirals: simultaneous determination of five protease inhibitors and three nonnucleoside transcriptase inhibitors in human plasma by a rapid high-performance liquid chromatography-mass spectrometry assay. Ther Drug Monit 2002;24: 380–388.

    Google Scholar 

  33. Volosov A, Alexander C, Ting L, Soldin SJ. Simple rapid method for quantification of antiretrovirals by liquid chromatography–tandem mass-spectrometry. Clin Biochem 2002;35: 99–103.

    Article  PubMed  CAS  Google Scholar 

  34. Ghoshal AK, Soldin SJ. Improved method for concurrent quantification of antiretrovirals by liquid chromatography-tandem mass spectrometry. Ther Drug Monit 2003;25: 541–543.

    Article  PubMed  CAS  Google Scholar 

  35. Soldin SJ, Rakhmanina NY, Spiegel HML, Sever JL. Therapeutic drug monitoring for patients with HIV infection: Children’s National Medical Center, Washington, DC Experience. Ther Drug Monit 2004;26: 107–109.

    Article  PubMed  Google Scholar 

  36. Rakhmanina NY, Cappardli EV, Van den Pocker JN, Williams K, Sever JL, Spiegel HML and Soldin SJ. Nevirapine Concentration in Nonstimulated Saliva: An Alternative to Plasma Sampling in Children with Human. Immunodeficiency Virus Infection. Ther Drug Monit 2007: 29; 110–117.

    Google Scholar 

Download references

Authors
  1. Steven J. Soldin PhD,ABCC,FACB
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pathology and Laboratory Medicine, University of Texas-Houston Medical School, Houston, TX

    Amitava Dasgupta PhD,DABCC,FACB

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press Inc

About this chapter

Cite this chapter

Soldin, S.J. (2008). Therapeutic Drug Monitoring in Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome. In: Dasgupta, A. (eds) Handbook of Drug Monitoring Methods. Humana Press. https://doi.org/10.1007/978-1-59745-031-7_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-031-7_10

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-780-8

  • Online ISBN: 978-1-59745-031-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation